Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Decreases By 93.8%

by · The Markets Daily

Xenetic Biosciences Inc (NASDAQ:XBIO – Get Free Report) saw a large decrease in short interest in December. As of December 15th, there was short interest totalling 500 shares, a decrease of 93.8% from the November 30th total of 8,100 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily volume of 24,400 shares, the days-to-cover ratio is currently 0.0 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “neutral” rating on shares of Xenetic Biosciences in a report on Thursday, December 5th.

View Our Latest Analysis on XBIO

Xenetic Biosciences Stock Performance

Shares of XBIO stock opened at $4.15 on Thursday. Xenetic Biosciences has a fifty-two week low of $2.78 and a fifty-two week high of $5.20. The company has a market cap of $6.40 million, a PE ratio of -1.56 and a beta of 2.24. The stock’s fifty day moving average price is $4.01 and its two-hundred day moving average price is $3.98.

Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.14). The company had revenue of $0.61 million during the quarter, compared to analyst estimates of $0.75 million. Xenetic Biosciences had a negative net margin of 161.63% and a negative return on equity of 49.51%. On average, equities analysts predict that Xenetic Biosciences will post -1.01 EPS for the current fiscal year.

Xenetic Biosciences Company Profile

(Get Free Report)

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.

Featured Articles